TABLE OF CONTENTS
1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 OVERVIEW OF HONDURAS SPECIFIC POLLEN ALLERGIES MARKET 16
1.4 LIMITATIONS 18
1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 CURRENCY AND PRICING 23
2.5 DBMR TRIPOD DATA VALIDATION MODEL 24
2.6 MULTIVARIATE MODELLING 27
2.7 PRODUCT TYPE LIFELINE CURVE 27
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
2.9 DBMR MARKET POSITION GRID 29
2.10 MARKET END USER COVERAGE GRID 30
2.11 VENDOR SHARE ANALYSIS 31
2.12 SECONDARY SOURCES 32
2.13 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 36
4.1 PESTEL ANALYSIS 37
4.2 PORTERS FIVE FORCES MODEL 38
4.3 CURRENT PATENTS THAT CAN BE USED IN ALLOPATHIC MEDICINES IN MEXICO- 39
4.4 INVENTION PATENT- 39
4.5 COUNTRY LEVEL ANALYSIS 40
5 REGULATIONS 43
5.1 HONDURAS 43
6 MARKET OVERVIEW 45
6.1 DRIVERS 47
6.1.1 INCREASE IN PREVALENCE OF ALLERGIC DISORDER 47
6.1.2 WIDE RANGE OF PRODUCT PORTFOLIOS OFFERED BY MAJOR PLAYER 47
6.1.3 IMPACT OF POLLEN ALLERGIES ON PAEDIATRICS POPULATION 48
6.1.4 HEALTH SECTOR REFORM AND EXPANSION OF PROGRAMMES TO BOOST HEALTHCARE SPENDING 48
6.2 RESTRAINTS 49
6.2.1 SIDE EFFECTS ASSOCIATED WITH THE USE OF DRUGS 49
6.2.2 INCREASE IN TREND OF USING HOME REMEDIES/PHYTOCHEMICALS 49
6.3 OPPORTUNITIES 50
6.3.1 INCREASE IN THE ENVIRONMENTAL POLLUTION 50
6.3.2 AWARENESS OF THE USE OF OTC PRODUCTS 50
6.3.3 RELAXATION OF RULES ON DIRECT-TO-CONSUMER ADVERTISING 50
6.4 CHALLENGES 51
6.4.1 INCREASE IN ABUSE POTENTIAL 51
6.4.2 INTELLECTUAL PROPERTY RIGHTS LAW 52
7 HONDURAS SPECIFIC POLLEN ALLERGIES MARKET, BY DRUG TYPE 53
7.1 OVERVIEW 54
7.2 ANTIHISTAMINE 55
7.2.1 ANTIHISTAMINE, BY DRUG TYPE 56
7.2.2 LEVOCETIRIZINE 56
7.2.3 CETIRIZINE 57
7.2.4 LORATIDINE 57
7.2.5 DIPHENHYDRAMINE 57
7.2.6 CHLORPHENIRAMINE 57
7.2.7 FEXOFENADINE 58
7.3 CORTICOSTEROIDS 58
7.3.1 FLUTICASONE PROPIONATE 59
7.3.2 TRIAMCINOLONE/TRIAMCINOLONE ACETONOID 60
7.3.3 CROMOLYN SODIUM 60
7.3.4 OTHERS 60
7.4 DECONGESTANTS 61
7.4.1 DECONGESTANTS, BY DRUG TYPE 61
7.4.2 PSEUDOEPHEDRINE 62
7.4.3 PHENYLEPHRINE 62
7.4.4 OXYMETAZOLINE 63
7.4.5 OTHERS 63
7.5 ANTICHOLINERGICS 63
7.5.1 ANTICHOLINERGICS, BY DRUG TYPE 64
7.5.2 IPRATROPIUM BROMIDE 64
7.5.3 OTHERS 65
7.6 OTHERS 65
8 HONDURAS SPECIFIC POLLEN ALLERGIES MARKET, BY PRODUCTS 66
8.1 OVERVIEW 67
8.2 INSTRUMENTS 68
8.2.1 IMMUNO ASSAY ANALYZER 69
8.2.2 PRODUCTS, BY IMMUNOASSAY ANALYZER 70
8.3 RADIO IMMUNO ASSAY (RIA) 70
8.4 COUNTING IMMUNO ASSAY (CIA) 70
8.5 ENZYME LINKED IMMUNO-SORBENT ASSAYS (ELISA) 70
8.6 FLUOROIMMNOASSAY (FIA) 71
8.7 CHEMILUMINESCENCE ASSAY 71
8.7.1 LUMINOMETERS 72
8.8 REAGENTS AND KITS 72
8.9 OTHERS 73
9 HONDURAS SPECIFIC POLLEN ALLERGIES MARKET, BY DIAGNOSTIC TEST 74
9.1 OVERVIEW 75
9.2 IN VIVO TEST 76
9.2.1 IN VIVO TEST, BY DIAGNOSTIC TEST 76
9.2.2 SKIN PRICK 77
9.2.2.1 SKIN PRICK, BY DIAGNOSTIC TEST 77
9.2.2.2 GREER PRICK 77
9.2.3 THE STELLAR POINT 78
9.2.4 PHAZET 78
9.2.5 BIFURCATED SMALLPOX VACCINATION TEST 78
9.2.6 23G INTRAVENOUS NEEDLE 79
9.2.7 OTHERS 79
9.2.8 PATCH TEST 79
9.2.9 INTRADERMAL TEST 80
9.3 IN VITRO TEST 80
9.3.1 IN VITRO TEST, BY DIAGNOSTIC TEST 81
9.3.2 SERUM SPECIFIC IGE ASSAY 81
9.3.3 TOTAL IGE ASSAY 81
9.3.4 BASOPHIL ACTIVATION TEST 82
10 HONDURAS SPECIFIC POLLEN ALLERGIES MARKET, BY END USER 83
10.1 OVERVIEW 84
10.2 HOSPITALS 85
10.3 DIAGNOSTICS LABORATORIES 85
10.4 ACADEMIC AND RESEARCH INSTITUTES 86
10.5 OTHERS 87
11 HONDURAS SPECIFIC POLLEN ALLERGIES MARKET, BY DISTRIBUTION CHANNEL 88
11.1 OVERVIEW 89
11.2 DIRECT TENDER 90
11.3 RETAIL SALES 90
11.3.1 RETAIL SALES, BY TYPE 91
11.3.2 HOSPITAL PHARMACY 91
11.3.3 RETAIL PHARMACY 92
11.3.4 ONLINE PHARMACY 92
12 HONDURAS SPECIFIC POLLEN ALLERGIES MARKET: COMPANY LANDSCAPE 93
12.1 COMPANY SHARE ANALYSIS: HONDURAS SPECIFIC POLLEN ALLERGIES MARKET 93
13 SWOT ANALYSIS 94
14 COMPANY PROFILE 95
14.1 GLAXOSMITHKLINE PLC 95
14.1.1 COMPANY SNAPSHOT 95
14.1.2 REVENUE ANALYSIS 95
14.1.3 PRODUCT PORTFOLIO 96
14.1.4 RECENT DEVELOPMENTS 96
14.2 JOHNSON & JOHNSON SERVICES, INC 97
14.2.1 COMPANY SNAPSHOT 97
14.2.2 REVENUE ANALYSIS 97
14.2.3 PRODUCT PORTFOLIO 98
14.2.4 RECENT DEVELOPMENTS 98
14.3 PERRIGO COMPANY PLC 99
14.3.1 COMPANY SNAPSHOT 99
14.3.2 REVENUE ANALYSIS 99
14.3.3 PRODUCT PORTFOLIO 100
14.3.4 RECENT DEVELOPMENTS 100
14.4 SIEMENS HEALTHCARE GMBH 101
14.4.1 COMPANY SNAPSHOT 101
14.4.2 REVENUE ANALYSIS 101
14.4.3 PRODUCT PORTFOLIO 102
14.4.4 RECENT DEVELOPMENTS 102
14.5 THERMO FISHER SCIENTIFIC INC. 103
14.5.1 COMPANY SNAPSHOT 103
14.5.2 REVENUE ANALYSIS 103
14.5.3 PRODUCT PORTFOLIO 104
14.5.4 RECENT DEVELOPMENT 104
14.6 BAYER AG 105
14.6.1 COMPANY SNAPSHOT 105
14.6.2 REVENUE ANALYSIS 105
14.6.3 PRODUCT PORTFOLIO 106
14.6.4 RECENT DEVELOPMENT 106
14.7 ALCON INC. 107
14.7.1 COMPANY SNAPSHOT 107
14.7.2 REVENUE ANALYSIS 107
14.7.3 PRODUCT PORTFOLIO 108
14.7.4 RECENT DEVELOPMENTS 108
14.8 BIOMRIEUX, SA. 109
14.8.1 COMPANY SNAPSHOT 109
14.8.2 REVENUE ANALYSIS 109
14.8.3 PRODUCT PORTFOLIO 110
14.8.4 RECENT DEVELOPMENTS 110
14.9 CINFA LABORATORIES 111
14.9.1 COMPANY SNAPSHOT 111
14.9.2 PRODUCT PORTFOLIO 111
14.9.3 RECENT DEVELOPMENT 111
14.10 CIRCASSIA 112
14.10.1 COMPANY SNAPSHOT 112
14.10.2 REVENUE ANALYSIS 112
14.10.3 PRODUCT PORTFOLIO 113
14.10.4 RECENT DEVELOPMENTS 113
14.11 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 114
14.11.1 COMPANY SNAPSHOT 114
14.11.2 PRODUCT PORTFOLIO 114
14.11.3 RECENT DEVELOPMENTS 115
14.12 LINCOLN DIAGNOSTICS, INC. 116
14.12.1 COMPANY SNAPSHOT 116
14.12.2 PRODUCT PORTFOLIO 116
14.12.3 RECENT DEVELOPMENTS 116
14.13 MINARIS MEDICAL AMERICA, INC. 117
14.13.1 COMPANY SNAPSHOT 117
14.13.2 PRODUCT PORTFOLIO 117
14.13.3 RECENT DEVELOPMENTS 117
14.14 PRESTIGE CONSUMER HEALTHCARE INC. 118
14.14.1 COMPANY SNAPSHOT 118
14.14.2 REVENUE ANALYSIS 118
14.14.3 PRODUCT PORTFOLIO 119
14.14.4 RECENT DEVELOPMENT 119
14.15 QUEST DIAGNOSTICS INCORPORATED 120
14.15.1 COMPANY SNAPSHOT 120
14.15.2 REVENUE ANALYSIS 120
14.15.3 PRODUCT PORTFOLIO 121
14.15.4 RECENT DEVELOPMENT 121
14.16 SANOFI 122
14.16.1 COMPANY SNAPSHOT 122
14.16.2 REVENUE ANALYSIS 122
14.16.3 PRODUCT PORTFOLIO 123
14.16.4 RECENT DEVELOPMENTS 123
15 QUESTIONNAIRE 124
16 RELATED REPORTS 127

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.